SWITCHED ON
The daily technology series nobody asked for but everyone needed
The Mosquito Problem: Gene Drives and the Ethics of Rewriting a Species
Malaria kills roughly 600,000 people a year, most of them children under five in Sub-Saharan Africa. We now have a technology that could plausibly eliminate the mosquito species that transmits it, permanently, across an entire continent. The question of whether we should is one of the hardest in this entire series.
A gene drive is different from every other genetic technology we have covered in this series because it is designed not to modify an individual organism but to spread a genetic change through an entire wild population, permanently, without further human intervention after release. We have never had a technology quite like this before. We should be correspondingly careful about how we think through it.
Yesterday we examined AI weather forecasting's genuine breakthroughs, the well-documented life-saving power of early warning systems, the Maui wildfire tragedy as a case study in last-mile warning failure, and the stark climate adaptation finance gap facing the countries with the least capacity to close it. Today we are addressing a technology that this series has been building toward since the CRISPR episode in Season One: gene drives, and specifically their most advanced and most consequential proposed application — the genetic elimination of the mosquito species responsible for transmitting malaria across Sub-Saharan Africa. This is one of the most ethically serious topics we will cover. It deserves unhurried, careful treatment, and that is what we are going to try to give it.
01 — What a Gene Drive Actually Is
Normal genetic inheritance follows Mendelian rules — an offspring has roughly a fifty percent chance of inheriting any given gene variant from each parent, meaning a genetic modification introduced into a wild population through conventional means would typically be diluted and eventually disappear over generations, as normal selection pressures and random mating work against it. A gene drive is a genetic element engineered, using CRISPR technology, to bias inheritance dramatically in its own favour — copying itself onto the corresponding chromosome from the other parent, such that offspring inherit it at rates approaching 100 percent rather than 50 percent. This means a gene drive released into even a small number of individuals can spread through an entire wild population within a relatively small number of generations, in a way that ordinary genetic modifications cannot.
Target Malaria, a not-for-profit research consortium funded substantially by the Bill and Melinda Gates Foundation and Open Philanthropy, has developed a gene drive targeting Anopheles gambiae, one of the primary mosquito species responsible for malaria transmission in Sub-Saharan Africa. The specific drive under development targets a gene involved in female fertility, designed so that as the drive spreads through the population, an increasing proportion of females become infertile, eventually causing the local population to collapse. Because male mosquitoes do not bite or transmit malaria — only females, which require blood meals to produce eggs — the approach targets the sex responsible for disease transmission specifically.
Every previous technology in this series that modifies an organism's genetics operates on individuals — a crop variety, a gene therapy patient, an edited embryo. A gene drive is designed to alter an entire wild species, across its full range, permanently, through a mechanism that continues to operate and spread without further human intervention after the initial release. This is a genuinely different category of intervention in the natural world.
02 — The Case For
The humanitarian case for pursuing gene drive-based malaria elimination is powerful and should be stated with the seriousness it deserves. Malaria killed an estimated 608,000 people in 2022, according to World Health Organization data, the overwhelming majority of them children under five in Sub-Saharan Africa. This is a death toll comparable to a major war, recurring annually, concentrated in some of the world's poorest countries, caused by a disease that is preventable and treatable but that existing interventions — bed nets, indoor spraying, antimalarial drugs, and the RTS,S and R21 vaccines approved in 2021 and 2023 respectively — have not eliminated despite decades of sustained global health investment.
Existing malaria control methods have plateaued in their effectiveness, partly due to growing insecticide and drug resistance, and partly due to the sheer logistical challenge of maintaining bed net and spraying coverage across vast and often remote populations year after year. A gene drive, if it works as designed, would not require this ongoing logistical effort — it spreads and sustains itself through the mosquito population's own reproduction, potentially achieving a level of sustained suppression that repeated annual interventions struggle to maintain. Modelling by Target Malaria and independent researchers suggests that a successful gene drive deployment could substantially reduce or locally eliminate the primary malaria vector across large geographic areas, with corresponding reductions in disease burden that existing tools have not achieved despite enormous investment.
03 — The Case Against and the Genuine Uncertainties
The ecological case for caution is equally serious and rests on the fundamental novelty and irreversibility of the intervention. Anopheles gambiae, like every species, occupies an ecological niche — it is prey for various predators, and while its role in broader ecosystem function is not fully mapped, the precautionary principle that has appeared repeatedly throughout this series applies with particular force to an intervention designed to be self-sustaining and difficult or impossible to reverse once released into the wild.
The technical uncertainties are substantial. Gene drives could evolve resistance — mosquitoes carrying natural genetic variants that resist the drive's mechanism could be selected for over generations, potentially rendering the intervention ineffective after initial success, a dynamic that has already been observed in laboratory gene drive experiments and that requires ongoing technical refinement to address. Gene drives could spread beyond their intended geographic range — mosquitoes do not respect national borders, and a drive released in one country could spread to neighbouring countries that had not consented to or been consulted about the intervention, raising serious questions about cross-border governance and consent that current international frameworks are not well equipped to address. And the ecological consequences of significantly reducing or eliminating a species across a continental range, even a species widely regarded as a disease vector rather than a keystone species, are not fully predictable, because ecosystems are complex and the downstream effects of removing any component are difficult to model comprehensively in advance.
Civil society organisations in several African countries, along with some international environmental and Indigenous rights groups, have raised concerns about the governance of gene drive trials — questioning whether the consent processes in affected communities have been adequate, whether the research is being conducted with sufficient local scientific leadership and benefit-sharing rather than primarily by and for Northern research institutions and funders, and whether the risk-benefit calculation is being made by the people who will actually live with the consequences of an irreversible intervention in their local ecosystem.
04 — Where the Research Actually Stands
Target Malaria has conducted a phased research programme, beginning with non-gene-drive genetically modified mosquitoes released in small-scale trials in Burkina Faso in 2019 — modified to be sterile rather than carrying a self-propagating drive, specifically designed as a lower-risk step to build community engagement, regulatory experience, and technical validation before any actual gene drive release is considered. This phased, deliberately cautious approach — years of preliminary research, regulatory engagement, and community consultation before any self-propagating gene drive is released — reflects the research consortium's stated recognition that the technology's novelty and irreversibility demand a slower and more careful pathway than conventional genetic modification research.
As of 2026, no self-sustaining gene drive mosquito has been released into the wild anywhere in the world. The research remains in contained laboratory and, for the sterile precursor technology, small-scale field trial phases. The regulatory pathway for an actual gene drive release would require approval from national biosafety authorities in the countries involved, and the scientific and ethical review processes for a technology this novel are still being developed in real time alongside the research itself, guided partly by frameworks developed by the WHO and other international bodies specifically for gene drive technology.
05 — Who Should Decide, and How
The deepest question raised by gene drive technology is not primarily technical but is about governance and consent: who has the legitimate authority to decide whether an irreversible, self-propagating, potentially cross-border intervention in a wild ecosystem should proceed, and through what process should that decision be made?
The most defensible answer, and the one that Target Malaria and similar research consortia have increasingly moved toward, is that the affected communities and countries must be the primary decision-makers, with genuinely informed consent processes, substantial local scientific capacity building rather than dependence on external expertise, and governance structures that account for the cross-border nature of the intervention given that mosquito populations and potentially the gene drive itself do not respect national boundaries. This is more easily stated as a principle than implemented in practice, given the genuine disparities in scientific and regulatory capacity between the well-resourced international research consortia developing the technology and the national and local institutions in the countries where it would be deployed.
What is clear is that the malaria burden this technology aims to address is a genuine humanitarian catastrophe that existing tools have not solved, and the technology itself represents a genuinely novel category of intervention whose risks are not fully characterisable through the standard risk assessment frameworks developed for less permanent and less self-propagating interventions. Both of these facts are true simultaneously, and the tension between them — the moral urgency of a preventable death toll in the hundreds of thousands annually, against the precautionary case for extreme caution before deploying an irreversible technology in a living ecosystem — does not have a comfortable resolution. It requires the kind of careful, patient, community-led decision-making that this technology's development has, to its credit, increasingly tried to build in, even as the fundamental ethical tension remains unresolved.
Tomorrow we are shifting from biology to physics — specifically to quantum sensing, a less publicised sibling of quantum computing that is quietly producing some of the most immediately useful applications of quantum technology, from GPS-independent navigation to early earthquake detection. See you then.
Switched On is a daily technology series covering the ideas, systems, and arguments shaping the digital world. Opinionated. Witty. Occasionally wrong. Always worth the argument.
